A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT03367403
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- Donanemab — DRUGAdministered IV
- Placebo — DRUGAdministered IV
- LY3202626 — DRUGAdministered orally
Study Details
The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.
Key Dates
- Start date
- Dec 18, 2017
- Status verified
- Sep 2022
- Primary completion
- Dec 4, 2020
- Completion
- Sep 21, 2021
Study Design
- Enrollment
- 272 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Donanemab Monotherapy (Donanemab-M)Participants received 700 milligram (mg) donanemab intravenously (IV) every 4 weeks (Q4W) x 3 doses, then 1400 mg donanemab IV Q4W for up to 72 weeks.
- Placebo Comparator: PlaceboParticipants received placebo IV Q4W for up to 72 weeks.
- Experimental: Donanemab in Combination With LY3202626 (Donanemab-C)Participants received 700 mg donanemab IV Q4W x 3 doses, then 1400 mg donanemab IV Q4W in combination with 12 mg of LY3202626 orally for up to 72 weeks. As per protocol amendment (d) approved on Oct 9, 2018, donanemab in combination with LY3202626 (donanemab-C) arm discontinued as there was a low probability of identifying a statistically significant effect of 12mg of LY3202626 slowing cognitive decline.
Primary Outcome Measure
Change From Baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS) Score [ Time Frame: Baseline, 76 Weeks ]
Locations (56)
Find similar trials in Phoenix, AZ
By condition
By specialty
By research site
Banner Alzheimer's Institute· Phoenix, AZBanner Sun Health Research Institute· Sun City, AZNeurology Center of North Orange County· Fullerton, CAInstitute for Memory Impairment & Neurological Disorders· Irvine, CAIrvine Clinical Research Center· Irvine, CAPharmacology Research Institute· Newport Beach, CA
Related Studies
- Alzheimer's Disease Genetics StudyRecruiting · Indiana University · Nationwide, Indiana
- F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)Enrolling By Invitation · Washington University School of Medicine · St Louis, Missouri
- F 18 T807 Tau PET Imaging of Alzheimer's DiseaseRecruiting · Tammie L. S. Benzinger, MD, PhD · St Louis, Missouri
- GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) GenotypeEnrolling By Invitation · Banner Health · Phoenix, Arizona